MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced the results of two health outcomes studies and a placebo controlled randomized trial presented at the American Thoracic Society (ATS) 2015 Annual Meeting in Denver. Results from these studies demonstrated that a substantial proportion of hospitalized chronic obstructive pulmonary disease (COPD) patients are not provided maintenance treatments; one in three patients report low confidence in using COPD devices and a majority of these patients have low treatment adherence; and more patients on Brovana® (arformoterol tartrate) Inhalation Solution reported clinically significant improvements in health-status compared with placebo.
Help employers find you! Check out all the jobs and post your resume.
